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Abstract
Neoadjuvant chemotherapy for breast cancer has a well-estab-
lished role in the management of patients with locally advanced or
early stage disease. Multiple trials have demonstrated superior
survival outcomes in individuals achieving a pathologic complete
response at the time of definitive surgery, and sophisticated
genetic methods may predict which patients will be in this
category. Those with less than a pathologic complete response
remain at significant risk of recurrent disease, and currently no
further standard therapy exists. Ongoing studies of novel agents
may lead to improved therapeutic outcomes for this high-risk
population.
Neoadjuvant or preoperative chemotherapy for operable
breast cancer treatment was developed to achieve the goals
of cytoreduction, with subsequent improvement in the ability
to perform breast conservation, treatment of occult micro-
metastatic disease, and assessment of in vivo sensitivity to a
treatment regimen [1]. Multiple trials have demonstrated the
benefits and role of treatment with neoadjuvant; however, few
studies have evaluated the management of patients after the
completion of neoadjuvant therapy, especially those with a
suboptimal response.
Several large clinical trials have evaluated the role of
neoadjuvant chemotherapy for breast cancer. National
Surgical Adjuvant Breast and Bowel Project (NSABP) B-18
randomized 1,523 patients with operable breast cancer to
receive four cycles of adriamycin and cyclophosphamide
(AC) either before or after definitive surgery. In the group
treated with neoadjuvant, a rate of pathologic complete
response (pCR) in the breast of 13% was observed, with a
significantly higher rate of breast conservation (67% versus
60%; P = 0.002) At a median follow-up of 9 years, compari-
son between the groups treated with neoadjuvant and with
adjuvant demonstrated no differences in either disease-free
survival (DFS) or overall survival (OS). However, when segre-
gated by pathologic response to treatment with neoadjuvant,
individuals achieving a pCR experienced significantly
improved outcomes compared with non-pCR subjects,
including 9-year DFS (75% versus 58%) and OS (85%
versus 73%), and a 50% decrease in the risk of death
compared with all other pathologic outcomes (relative risk
0.50, 95% confidence interval 0.32 to 0.78) [2,3]. In a similar
study, the European Organization for Research and
Treatment of Cancer (EORTC) randomized 698 subjects to
anthracycline-based chemotherapy before or after surgery.
Again, despite there being no differences in DFS or OS
between the neoadjuvant and adjuvant groups, the pCR
subgroup, defined as no residual invasive tumor in breast or
lymph node tissue, did show improved OS (hazard ratio (HR)
0.86, 95% confidence interval 0.77 to 0.96, P = 0.008) [4].
To investigate the role of exposure to neoadjuvant taxane, the
NSABP randomized 2,411 subjects in study B-27 to
neoadjuvant AC alone, to neoadjuvant AC and docetaxel
before surgery, or to neoadjuvant AC with adjuvant docetaxel
after surgery. The addition of the preoperative taxane led to
an increased rate of pCR (26% with docetaxel versus 14%
without docetaxel, P < 0.001); because pCR was defined in
the breast tissue only, removing the 15% of patients
categorized as pCR with continued lymph node involvement
leads to true pCR rates of 21.8% with docetaxel versus
11.5% without docetaxel [5]. At a median follow-up of
6.5 years, individuals achieving pCR demonstrated signifi-
cantly improved survival compared with those without pCR
(DFS HR 0.45, P < 0.001; OS HR 0.33, P < 0.0001) [6].
Efforts have been made to identify more accurately patients
who are more likely to achieve pCR with neoadjuvant chemo-
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therapy. Historical experience suggests that hormone-
receptor negative tumors are far more likely to achieve pCR
than hormone-receptor positive tumors (20% versus 5% in a
retrospective analysis) [7], and similarly ductal carcinomas
may often achieve pCR whereas lobular carcinomas rarely do
(less than 3% in larger experiences with up to 100 patients).
A recently reported nomogram uses clinical and pathologic
variables to predict likelihood of pCR in the breast and axilla
with neoadjuvant anthracycline-based treatment. This
nomogram includes independent predictors such as clinical
stage at diagnosis, hormone receptor status, histologic
grade, and number of preoperative chemotherapy cycles, and
is able to predict pCR with reasonable accuracy [8].
Molecular assays have also been used to predict the
likelihood of pCR in patients receiving neoadjuvant chemo-
therapy. The 21-gene recurrence score assay, which quanti-
fies the levels of expression of 16 genes involved in breast
cancer pathogenesis, has been shown to predict whether
patients are likely to achieve pCR in response to anthra-
cycline- and taxane-based chemotherapy [9]. Tumors with
low recurrence scores, which tend to have higher levels of
hormone receptor expression, lower levels of HER2
expression, and lower grade, are far less likely to reach pCR
than tumors with higher recurrence scores. Gene expression
arrays can also classify tumor specimens into several
subgroups, including the hormone-receptor positive luminal
subtypes A and B, as well as the HER2+/ER– (where ER is
estrogen receptor) subtype and the basal-like subtype, which
typically underexpresses both hormone receptors and Her2;
variable prognoses are observed for different subtypes
[10-12]. Microarray analysis of preoperative samples before
neoadjuvant anthracycline-based chemotherapy has demon-
strated significant differences in the rates of pCR among the
four molecular subtypes, with the highest rates of pCR seen
in the basal-like and HER2+ subgroups (45%) and lower
rates for the luminal tumors (6%) [13]. Among the hormone-
receptor negative patients who fail to achieve pCR, there is a
particularly high rate of early recurrence [14].
Although a lack of pCR portends a worse outcome,
developing evidence suggests that there may be hetero-
geneity in outcome within the non-pCR group. Residual
cancer burden (RCB), an index calculated from measure-
ments of residual disease size and cellularity in the primary
tumor and nodal metastases, has been evaluated in patients
participating in two studies of neoadjuvant chemotherapy at
the MD Anderson Cancer Center. Using a three-tier grading
system, RCB was found to be a continuous predictor of
DFS, with the patients at highest risk having the highest
category of RCB [15]. Furthermore, expression array
analysis of samples from NSABP B-27 demonstrates
segregation of the non-pCR group into low-risk and high-risk
categories, with differential survival outcomes [16]. Future
use of these novel prognostic tools may better discriminate
which patients with residual disease should receive further
treatment from those with a favorable enough prognosis to
defer further therapy.
Currently, for most patients who do not achieve pCR after
treatment with a well-studied neoadjuvant chemotherapy
regimen [17], there is no evidence to support the use of
further adjuvant chemotherapy. The only exception would be
a patient who received only a portion of the chemotherapy
regimen (for example a patient who received four cycles of
AC and could go on to receive four additional cycles of a
taxane). For the patient who has received a complete course
of chemotherapy, any additional chemotherapy should be
offered in the context of a clinical trial. Patients with
hormone-receptor positive or Her2-positive disease certainly
should receive appropriate adjuvant endocrine or
trastuzumab therapy. Considering that residual disease may
reflect resistance to the neoadjuvant chemotherapy, pilot
trials have attempted to offer further non-cross-resistant
chemotherapy in the adjuvant setting. In a trial from the MD
Anderson Cancer Center, 110 patients who had received
neoadjuvant VACP (vincristine, doxorubicin, cyclophos-
phamide, and prednisone) without pCR were randomized to
further treatment with VACP or VbMP (vinblastine,
methotrexate, and prednisone). Results demonstrated that
further treatment with adjuvant was tolerable, with the
suggestion of improved outcomes in the VbMP arm over the
VACP arm (OS 65% versus 47%, P = 0.06) [18]. In the
small ICARO 1 study, presented in abstract form at the
2006 San Antonio Breast Cancer Symposium, 48 patients
with clinical T4 disease were treated with neoadjuvant PEV
(cisplatin, epirubicin, and vinorelbine), surgery, radiation,
adjuvant CMF (cyclophosphamide, methotrexate, and 5-
fluorouracil) for six cycles, and endocrine therapy if
indicated. Individuals who did not achieve pCR at the time of
surgery (n = 35) were randomized to observation (n = 28) or
reinduction therapy with epirubicin and sequential docetaxel
(n = 7). At a median follow-up of 72 months, DFS and OS
were significantly better in the reinduction group than in the
observation group (100% versus 53%, P = 0.009; 100%
versus 68%, P = 0.05, respectively) [19]. Although
provocative, the numbers in this trial are too small for any
definitive conclusions to be drawn. However, both studies
suggest that further non-cross-reactive treatment may be of
value. The GeparTrio study examined the effect of providing
a non-cross-reactive regimen (NX; vinorelbine and capecita-
bine) to individuals without evidence of clinical response
after two cycles of preoperative TAC (docetaxel,
doxorubicin, cyclophosphamide). In the 74 patients studied,
pCR rates were not significantly improved with the non-
cross-reactive NX regimen compared with those receiving
further TAC (3.1% versus 7.3%) [20]. Despite the apparent
lack of benefit from the non-cross-reactive regimen in this
setting, the role of a novel regimen for non-responders
completing an entire, rather than an abbreviated, course of
preoperative treatment is unknown, as are long-term effects
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An alternative mechanism for targeting chemotherapy-
resistant disease may be through novel treatment approa-
ches, such as the use of angiogenesis inhibitors. The primary
agent in this class, bevacizumab, has already demonstrated
marked benefits in several types of solid tumor [21,22]. In
metastatic breast cancer, initial examination of bevacizumab
with capecitabine chemotherapy in pretreated disease
showed an improved response rate that did not translate into
improved DFS or OS [23]. Subsequently, the addition of
bevacizumab to paclitaxel chemotherapy in the first-line
setting showed improvements in both response and DFS
[24]. Another tool in targeting angiogenesis, metronomic
chemotherapy (continuous low-dose oral treatment with
cyclophosphamide and methotrexate) has also demonstrated
activity in the metastatic setting in combination with
bevacizumab [25]. It is possible that other novel biological
therapies that show promise in breast cancer treatment may
also have a role in the post-preoperative setting.
An ongoing multicenter pilot trial, led by investigators at the
Dana-Farber Cancer Institute, is evaluating the feasibility and
toxicity of 1 year of angiogenesis inhibitor therapy for
individuals with less than a pCR after neoadjuvant chemo-
therapy (see Figure 1). Eligibility includes residual invasive
disease in the breast or lymph node tissue after treatment
with neoadjuvant, and receipt of a standard chemotherapy
regimen, either preoperatively or postoperatively. In the first of
three cohorts, 40 women have been treated with 1 year of
adjuvant bevacizumab. This cohort included 45% women
with stage III disease at diagnosis and 58% who were
hormone-receptor positive. Therapy was generally well
tolerated, with treatment-related toxicities including mild
arthralgias (50%), headache (50%), epistaxis (20%), and
hypertension (23%). Significant toxicities included one case
of reversible posterior leukencephalopathy and one patient
with gastrointestinal bleeding. With a median follow-up of 8
months, four patients have recurred, underscoring the high-
risk nature of this population. Extended follow-up from this
study will evaluate possible long-term cardiovascular side
effects from prolonged bevacizumab exposure. Accrual
continues in the two other cohorts, which offer 1 year of
bevacizumab paired with oral chemotherapy, either 6 months
of metronomic chemotherapy or six cycles of capecitabine.
Data from this pilot study will be used to design a phase III
trial for this patient population randomizing to one of three
arms: 1 year of bevacizumab, six cycles of capecitabine, or a
combination of the two [26].
Conclusion
Neoadjuvant chemotherapy is an evolving strategy for treating
locally advanced and early stage breast cancer. One potential
advantage of treatment with neoadjuvant therapy is the
opportunity to use pathologic response at the time of surgery
to stratify patients by risk and subsequently select those for
whom further therapeutic recommendations may be
beneficial. As yet, the use of such dynamic tumor response
information to guide clinical recommendations is in the
investigative stages. However, it is hoped that the design of
future clinical trials will allow an objective assessment of this
management approach.
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